More Articles

The preference policy in The Netherlands Policies & Legislation | Posted 18/06/2010

The Netherlands is threatening its generic manufacturing industry with its preference policy, according to Mr Frank Bongers, Chairman of Bond Van De Generieke Geneesmiddelenindustrie Nederland (Bog...

Opportunities arising from increased use of generics Reports | Posted 11/06/2010

Ensuring the sustainability of the generic medicines industry is one of the key elements in maintaining broad access to medicines for all. To meet increasing demand from more patients who are livin...

Challenges facing generic manufacturers in Europe Reports | Posted 11/06/2010

There are many challenges that may limit the competitiveness and sustainability of the European generics sector. Costs and pricing, especially in light of recent cost-cutting exercises in many Euro...

The role of generic medicines in Europe Reports | Posted 11/06/2010

The role of generic medicines has been to provide essential medicines that are both high quality and affordable throughout the EU. They have enabled increased access to medicines for patients and p...

The rising cost of health care in Europe Reports | Posted 11/06/2010

The ageing population and lifestyle changes bring an increased burden on health care and consequently an increase in costs. This growing cost of health care is unavoidable, and drug expenditure is...

Is the quality of generic medicines under pressure? Generics/News | Posted 11/06/2010

“You get what you pay for” runs the old adage, and concerns are being expressed that a number of firms providing clopidogrel in Europe have all sourced the active ingredient from the same Indian fi...

EGA welcomes MEPs decisions on falsified medicines and pharmacovigilance reports Pharma News | Posted 11/06/2010

On 27 April 2010, ENVI (The Committee on the Environment, Public Health and Food Safety) of the European Parliament voted to adopt reports on both falsified medicines and pharmacovigilance. The mea...

FDA rejects second citizen petition for Teva’s glatiramer acetate drug Pharma News | Posted 04/06/2010

Teva Pharmaceutical Industries’ glatiramer acetate drug (Copaxone) is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.